Aptose Biosciences (APS.TO) on Thursday announced the publication of preclinical data for its lead hematology compound tuspetinib (TUS) in Cancer Research Communications, a journal of the American Association for Cancer Research (AACR).
The paper is the first preclinical profiling of tuspetinib, a once daily, oral kinase inhibitor currently in clinical development for treatment of acute myeloid leukemia (AML).
Aptose is now enrolling newly diagnosed AML patients in a Phase 1/2 clinical study to receive the tuspetinib with two other medications. Clinical studies in patients with relapsed or refractory AML receiving TUS single agent or with one other medication have been completed.
"The non-clinical findings presented in the publication suggest that TUS will demonstrate favorable safety and a breadth of antileukemic activity across AML patient populations with a diversity of adverse mutations, and the initial clinical data is bearing that out," said CEO William Rice.
The company's shares were last seen up $0.01 to $0.27 on the Toronto Stock Exchange.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.